An incentive-based approach for improving data reproducibility

In the editorial published in Science Translational Medicine, Michael Rosenblatt, Merck’s executive vice president and chief medical officer, said bad results from academic labs caused pharmaceutical companies to waste millions and “threatens the entire biomedical research enterprise.” He suggests an incentive-based approach for improving data reproducibility that is essentially a “full or partial money-back guarantee.” That is, if research that drug companies pay for turns out to be wrong, universities would have to give back the funding they got. Merck thinks this will put the pressure right where it belongs, on the scientists. Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *